Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ewing sarcoma].

Satoshi Hamanoue1, Atsushi Makimoto

  • 1Division of Pediatrics, National Cancer Center Hospital.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 16, 2007
PubMed
Summary
This summary is machine-generated.

Ewing sarcoma family tumors (ESFT) are rare bone cancers in young people. Modern treatments improve survival for localized disease, but metastatic ESFT remains challenging, driving ongoing international research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Efficacy of Tumor-Treating Fields (TTFields) Therapy for Pediatric High-Grade Glioma: Results of a Prespecified Interim Analysis of the First Three Cases.

Children (Basel, Switzerland)·2026
Same author

Post-transplantation gilteritinib maintenance therapy and therapeutic drug monitoring in pediatric acute myeloid leukemia with FLT3-internal tandem duplication.

Cancer chemotherapy and pharmacology·2026
Same author

Safety and efficacy of a helium-oxygen mix for pediatric respiratory failure associated with anatomical and functional stenotic lesions of the airway: a phase II clinical trial.

Respiratory medicine·2025
Same author

Unique Bone Marrow Findings of FDG-PET/CT in Acute Leukemia in Children: Comparison to Inflammatory Diseases.

Children (Basel, Switzerland)·2025
Same author

A case of acute promyelocytic leukemia complicated by mitochondrial disease.

International journal of hematology·2025
Same author

Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML).

Cancer chemotherapy and pharmacology·2024
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Pediatric Oncology
  • Molecular Biology

Context:

  • Ewing sarcoma is the second most common primary bone cancer in children and young adults.
  • Advances in molecular biology identified EWS-FLI1 translocations, classifying related tumors as Ewing sarcoma family tumors (ESFT).

Purpose:

  • To review the current understanding and treatment landscape of Ewing sarcoma family tumors.
  • To highlight the progress in multimodal therapeutic regimens and ongoing clinical trials.

Summary:

  • Multimodal therapy including chemotherapy, radiotherapy, and surgery has increased cure rates for localized ESFT to 60%.
  • Standard chemotherapy regimens vary between Europe (VACD) and North America (VDC-IE).
  • Metastatic ESFT has a poor prognosis with a 5-year event-free survival of 10-30%.

Related Experiment Videos

Impact:

  • Improved survival rates for localized ESFT due to collaborative international research and standardized treatments.
  • Ongoing clinical trials, such as EURO-E.W.I.N.G.99 and JESS, aim to further enhance cure rates for both localized and metastatic ESFT.
  • The identification of molecular markers like EWS-FLI1 aids in diagnosis and understanding of ESFT.